Pedro Felipe Gomes Nicz et al. Pedro Henrique M. Craveiro de Melo Pedro Henrique Ferro de Brito Eliane Nogueira Lima … Ricardo Cavalcante e Silva Maurício Lopes Prudente Fernando Henrique Fernandes Maurilio Onofre Deininger Marcelo Antônio Cartaxo Queiroga Lopes Fúlvio Soares Petrucci Fernando Roquette Reis Filho Marcos Antonio Marino Rodrigo de Castro Bernardes Eduardo Pessoa de Melo Marco Antonio Praça Oliveira José Armando Mangione Fernanda Marinho Mangione Carlos Henrique Eiras Falcão Estêvão Carvalho de Campos Martins Walter Lunardi Fernando Bacal Flávio Tarasoutchi Fábio Sândoli de Brito Jr
Abstract
Background
Percutaneous intervention in patients with bioprosthetic mitral valve dysfunction is an alternative to conventional surgical treatment.
Objectives
To report the first Brazilian experience with transseptal transcatheter bioprosthetic mitral valve-in-valve implantation (transseptal-TMVIV).
Methods
Patients with surgical bioprosthetic dysfunction submitted to transseptal-TMVIV in 12 Brazilian hospitals were included. The significance level adopted was p<0.05.
Results
From June/2016 to February/2019, 17 patients underwent transseptal-TMVIV. Their median age was 77 years (IQR,70-82) and median Society of Thoracic Surgeons predicted risk of mortality (STS-PROM) score was 8.7% (IQR,7.2-17.8). All patients had limiting symptoms of heart failure (FC≥III) and 5 (29.4%) had undergone more than one previous thoracotomy. Transseptal-TMVIV was successful in all patients. Echocardiographic assessment showed a significant reduction in mean mitral valve gradient (pre-intervention, 12±3.8 mmHg; post-intervention, 5.3±2.6 mmHg; p<0.001), in addition to an increase in mitral valve area (pre-intervention, 1.06±0.59 cm2; post-intervention, 2.18±0.36 cm2; p<0.001) sustained for 30 days. There was a significant and immediate reduction in the pulmonary artery systolic pressure, with an additional reduction in 30 days (pre-intervention, 68.9±16.4 mmHg; post-intervention, 57.7±16.5 mmHg; 30 days, 50.9±18.7 mmHg; p<0.001). During follow-up (median, 162 days; IQR, 102-411), significant clinical improvement (FC≤II) was observed in 87.5% of the patients. One patient (5.9%) had left ventricular outflow tract (LVOT) obstruction and died right after the procedure, and another died at 161 days of follow-up.
Conclusion
The first Brazilian experience with transseptal-TMVIV shows the safety and effectivity of the new technique. The LVOT obstruction is a potentially fatal complication, reinforcing the importance of patients’ selection and of procedural planning. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)
